Recent meta-analyses provide evidence supporting
the recommendation of pneumococcal polysaccharide
vaccine (PPV) to prevent invasivepneumococcal disease in adults, but, with regard
to adults with chronic illness, do not find compelling
evidence to support the routine use of PPV
to prevent all-cause pneumonia or mortality
[Moberley et al. 2013; Huss et al. 2009].
However, the 23-valent vaccine prevented
pneumococcal pneumonia and reduced mortality
due to pneumococcal pneumonia in nursinghome
residents in a randomized trial
[Maruyama et al. 2010]. Moreover, in a matched
casecontrol study in patients aged 65 years
and hospitalized with CAP, Domı´nguez and colleagues
found an effectiveness of 23.6% for the
PPV for preventing hospitalizations due to pneumonia
[Domı´nguez et al. 2010].